India’s animal health sector is set for a major shake-up. SeQuent Scientific Ltd, a leading global animal health company, and Viyash Lifesciences, an integrated pharmaceutical manufacturer, have received the National Company Law Tribunal (NCLT) approval for their merger—officially setting the stage for a transformed, scaled-up entity ready to compete globally.
This approval marks more than just a legal milestone. It signals a strategic leap forward for the combined business as it prepares to accelerate growth across the worldwide animal health landscape.
Together, SeQuent and Viyash now represent the largest animal health company from India, backed by strong financial performance:
The combined scale gives the new entity the financial muscle, R&D depth, and manufacturing capabilities required to compete with global players—and expand across both pet and farm animal health markets.
Global pet care is one of the fastest-growing healthcare segments. Rising pet adoption and new therapeutic needs are opening massive opportunities in:
The combined SeQuent–Viyash platform aims to mirror advancements from human pharma and bring them into pet health—where innovation demand is rising rapidly.
While human health has rapidly transitioned to generics, the animal health industry lags behind. This creates a substantial opening for the merged company to:
With advanced R&D and global supply capabilities, the combined entity is positioned to lead this generics wave.
The integration brings together complementary strengths:
For SeQuent, the merger revitalises its ability to pursue strategic acquisitions. For Viyash, it unlocks access to a global commercial and manufacturing footprint.
“This merger creates the platform to deliver world-class solutions for our customers… We have developed a comprehensive plan for integration that leverages synergies for growth and capability. The momentum reflected in our recent results is only the beginning.”
— Dr. Haribabu Bodepudi, Founder & CEO, Viyash
“We are pleased to receive NCLT approval, marking the start of a transformative journey… With this merger, the company will be uniquely positioned to deliver relevant, quality care for animals and set new benchmarks in innovation and customer trust.”
— Rajaram Narayanan, Managing Director & CEO, SeQuent
With regulatory approval in place, SeQuent and Viyash now move into the integration phase—aligning operations, optimising synergies, and building a next-generation animal health organisation.
The combined company aims to redefine global standards in:
As the global demand for animal health solutions surges, this merger positions the new entity at the forefront of opportunity.